Literature DB >> 21052656

Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.

Anita P Price1, Sara J Abramson, Sinchun Hwang, Alexander Chou, Roger Bartolotta, Paul Meyers, Douglas S Katz.   

Abstract

BACKGROUND: After observing metaphyseal changes in pediatric and young adult patients with osteosarcoma who were treated with pamidronate, we initiated a retrospective study to identify bone findings on computed radiography of the chest and extremities, chest CT, extremity MRI, and radionuclide bone scans in this population.
OBJECTIVE: To review the generalized skeletal imaging findings on computed radiography, CT, and MR examinations in patients with osteosarcoma (OS) receiving pamidronate.
MATERIALS AND METHODS: A retrospective review of 40 patients with newly diagnosed OS (mean age, 16.5 years) receiving pamidronate with chemotherapy were identified at one institution. Computed radiography, CT, MR, and bone scans on 36 patients were reviewed for osseous changes.
RESULTS: Dense metaphyseal bands at the growth plates in long bones, epiphyseal ossification centers, anterior rib ends, sternum and spine were observed. Osseous changes occurred on CT in 69% of patients, and on computed chest radiography in 53%. Bone-within-bone appearance in the spine and ossification centers was identified on computed radiography in 36%.
CONCLUSION: OS patients treated with pamidronate can develop metaphyseal sclerotic bands as well as epiphyseal and vertebral endplate sclerosis progressing to a bone-within-bone appearance. Findings occur more frequently in younger patients with open epiphyses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052656     DOI: 10.1007/s00247-010-1883-4

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  32 in total

1.  RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.

Authors:  Yohann Wittrant; François Lamoureux; Kanji Mori; Anne Riet; Akira Kamijo; Dominique Heymann; Françoise Redini
Journal:  Int J Oncol       Date:  2006-01       Impact factor: 5.650

2.  Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.

Authors:  Michele D Mignogna; Stefano Fedele; Lucio Lo Russo; Roberto Ciccarelli; Lorenzo Lo Muzio
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

3.  Bone densitometry in pediatric patients treated with pamidronate.

Authors:  Leslie E Grissom; Heidi H Kecskemethy; Steven J Bachrach; Charles McKay; H Theodore Harcke
Journal:  Pediatr Radiol       Date:  2005-01-18

4.  Quantification of metaphyseal modeling in children treated with bisphosphonates.

Authors:  Kate Ward; Christopher T Cowell; David G Little
Journal:  Bone       Date:  2005-06       Impact factor: 4.398

5.  Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs.

Authors:  Jenna A Ashton; James P Farese; Rowan J Milner; Linda M Lee-Ambrose; James M van Gilder
Journal:  Am J Vet Res       Date:  2005-05       Impact factor: 1.156

6.  Radiographic features of bisphosphonate therapy in pediatric patients.

Authors:  Leslie E Grissom; H Theodore Harcke
Journal:  Pediatr Radiol       Date:  2003-02-15

7.  Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.

Authors:  Nita L Seibel; Mark Krailo; Zhengjia Chen; John Healey; Philip P Breitfeld; Richard Drachtman; Brian Greffe; James Nachman; Helen Nadel; Judith K Sato; Paul A Meyers; Gregory H Reaman
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

8.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

Review 9.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

Review 10.  Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

Authors:  Sohita Dhillon; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more
  2 in total

Review 1.  Imaging of late complications of cancer therapy in children.

Authors:  Susan C Shelmerdine; Govind B Chavhan; Paul S Babyn; Paul C Nathan; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2016-12-01

2.  Radiographic and MR Imaging Findings of the Spine after Bisphosphonate Treatment, in a Child with Idiopathic Juvenile Osteoporosis.

Authors:  Olympia Papakonstantinou; Maria Sakalidou; Erato Atsali; Vasiliki Bizimi; Maria Mendrinou; Efthymia Alexopoulou
Journal:  Case Rep Radiol       Date:  2015-01-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.